Medical Distributors Surge: A Deeper Dive into Market Movements and Notable Tickers
π Medical Distributors experience a +strong performance in the past month. Current Buy/Sell Ratings suggest a Positive Outlook for stocks in the group.
Are you interested in the dynamic world of medical distributors and eager to optimize your trading strategies within this sector? Look no further! Our AI robots are tailored to meet your trading needs in the Group Medical Distributors arena.
π€ "Swing Trader, Popular Stocks: Price Action Trading Strategy (TA&FA)" provides you with a reliable and data-driven approach to trading within this sector. Whether you're a seasoned trader or just starting, this AI tool can assist you in making informed decisions.
πΌ For those seeking to capitalize on upward market trends, "Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA)" offers a simplified yet effective strategy. It's designed to empower traders to navigate and thrive in markets on the rise.
With these AI robots by your side, you'll be well-equipped to explore trading opportunities and make data-backed decisions in the ever-evolving world of medical distributors. Elevate your trading game today!
Tickers in this Group:Β
$EDAPΒ - $CAHΒ - $MCKΒ - $CORΒ -Β $HSICΒ -Β $OMIΒ -Β $PDCOΒ - $ZYXI
The Landscape of Medical Distributors
Medical distributors play a pivotal role in the healthcare ecosystem, bridging the gap between manufacturers and providers. Their core services, ranging from product distribution to inventory management, contribute significantly to the US healthcare sector's value. As per a report by Deloitte, these services infuse a value of $33 billion-$53 billion annually. Major players in this sector include giants like McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc., and Patterson Companies, Inc.
Market Cap: The Financial Magnitude
The medical distributors' industry has a collective market cap averaging at 8.9B. The spectrum is vast - from $MCK at a towering 61.9B to a modest $SNYR at 494.4K.
High and Low Price Notable News: The Peaks and Valleys
Key Players:
Recent News Highlights:
Volume: The Trading Buzz
Fundamental Analysis Ratings: The Deep Dive
Ticker Descriptions: Highlighting Key Players
π $CAH: Now trending upward after rising above its 50-day MA on October 04, 2023. Past trends suggest a 78% chance of continued uptrend.
π $ZYXI: Watch out! Entering the oversold zone as of October 13, 2023. Historically, it indicates potential for a price uptrend or consolidation soon.
π $PDCO: Positive vibes! MACD Histogram turned positive on September 21, 2023, with 82% chances of a continued rise.
π $COR: Bullish trend with the 10-day MA crossing over the 50-day MA on September 28, 2023. Past data indicates a 71% chance of continued upward movement.
π $MCK: Yet another MACD positive shift on September 12, 2023, with a strong 75% odds of maintaining the bullish trend.
π $EDAP: Positive MACD crossover on September 20, 2023, suggests an 84% probability of an upward trend in the coming month.
Β
The Medical Distributors sector is currently buzzing with positive vibes, reflected in its impressive gains and overall positive outlook. Traders should closely monitor the described tickers and watch for further market shifts. As always, it's essential to make informed decisions and keep an eye on these notable market movers. Happy trading! πππ
The 50-day moving average for FOCL moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FOCL as a result. In 71 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for FOCL turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
FOCL moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FOCL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where FOCL advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
FOCL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-48.608) is normal, around the industry mean (14.423). P/E Ratio (-3.192) is within average values for comparable stocks, (11.188). FOCL's Projected Growth (PEG Ratio) (8.100) is very high in comparison to the industry average of (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (1.919) is also within normal values, averaging (4.260).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. FOCLβs price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOCLβs unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of minimally invasive medical devices for urological diseases
Industry MedicalDistributors